FDA Guidance Allows Limited Foreign Data To Approve Devices With Postmarket Caveat
This article was originally published in The Gray Sheet
Executive Summary
As FDA puts more emphasis on postmarket data collection in its PMA approval process, the agency has released a final guidance on balancing premarket and postmarket studies.